Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical impact of radiotherapy for locally advanced pancreatic cancer.
Sawaki A, Hoki N, Ito S, Matsumoto K, Mizuno N, Hara K, Takagi T, Kobayashi Y, Sawai Y, Kawai H, Tajika M, Nakamura T, Yamao K. Sawaki A, et al. Among authors: tajika m. J Gastroenterol. 2009;44(12):1209-14. doi: 10.1007/s00535-009-0116-9. J Gastroenterol. 2009. PMID: 19705054
Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS.
Shitara K, Yokota T, Takahari D, Shibata T, Ura T, Utsunomiya S, Inaba Y, Yamaura H, Sato Y, Najima M, Kawai H, Tajika M, Sawaki A, Yatabe Y, Muro K. Shitara K, et al. Among authors: tajika m. Invest New Drugs. 2011 Aug;29(4):688-93. doi: 10.1007/s10637-009-9382-x. Epub 2010 Jan 14. Invest New Drugs. 2011. PMID: 20072801 Clinical Trial.
Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer.
Shitara K, Muro K, Ito S, Sawaki A, Tajika M, Kawai H, Yokota T, Takahari D, Shibata T, Ura T, Ito H, Hosono S, Kawase T, Watanabe M, Tajima K, Yatabe Y, Tanaka H, Matsuo K. Shitara K, et al. Among authors: tajika m. Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1311-9. doi: 10.1158/1055-9965.EPI-09-1257. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20447923
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Shitara K, Yuki S, Yoshida M, Takahari D, Utsunomiya S, Yokota T, Sato Y, Inaba Y, Tajika M, Kawai H, Yamaura H, Kato M, Yamazaki K, Komatsu Y, Muro K. Shitara K, et al. Among authors: tajika m. Invest New Drugs. 2012 Apr;30(2):787-93. doi: 10.1007/s10637-010-9615-z. Epub 2010 Dec 22. Invest New Drugs. 2012. PMID: 21174225 Clinical Trial.
Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer.
Shitara K, Ura T, Matsuo K, Takahari D, Yokota T, Yuki S, Yoshida M, Utsunomiya S, Sato Y, Yamaura H, Kato M, Inaba Y, Tajika M, Kawai H, Yamazaki K, Komatsu Y, Muro K. Shitara K, et al. Among authors: tajika m. Eur J Cancer. 2011 Dec;47(18):2673-80. doi: 10.1016/j.ejca.2011.05.015. Epub 2011 Jun 7. Eur J Cancer. 2011. PMID: 21652203
233 results